Adam Walsh
Stock Analyst at Roth MKM
(3.42)
# 2,232
Out of 4,345 analysts
119
Total ratings
43.2%
Success rate
5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Initiated Coverage: Buy | $36 | $16.95 | +112.39% | 1 | May 27, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $33.88 | +71.19% | 4 | May 13, 2026 | |
| EQ Equillium | Reiterated: Buy | $12 | $2.63 | +356.27% | 6 | May 13, 2026 | |
| INSM Insmed | Reiterated: Buy | $212 | $106.40 | +99.25% | 20 | May 8, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $7.66 | +161.10% | 5 | May 8, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $70 → $82 | $23.39 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $235.26 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Maintained: Buy | $298 | $27.70 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Maintained: Hold | n/a | $66.65 | n/a | 8 | Feb 10, 2020 | |
| KYNB Kyntra Bio | Maintained: Buy | $71 | $7.04 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $25 | $1.71 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $102.21 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $0.62 | n/a | 3 | Nov 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $437.22 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $52.46 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $220.93 | $7.45 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $295.63 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $16.68 | n/a | 2 | May 20, 2015 |
BioAge Labs
May 27, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $16.95
Upside: +112.39%
vTv Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $58
Current: $33.88
Upside: +71.19%
Equillium
May 13, 2026
Reiterated: Buy
Price Target: $12
Current: $2.63
Upside: +356.27%
Insmed
May 8, 2026
Reiterated: Buy
Price Target: $212
Current: $106.40
Upside: +99.25%
Arcturus Therapeutics Holdings
May 8, 2026
Reiterated: Buy
Price Target: $20
Current: $7.66
Upside: +161.10%
Ultragenyx Pharmaceutical
May 18, 2020
Maintained: Buy
Price Target: $70 → $82
Current: $23.39
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $235.26
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Maintained: Buy
Price Target: $298
Current: $27.70
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Maintained: Hold
Price Target: n/a
Current: $66.65
Upside: n/a
Kyntra Bio
Nov 12, 2019
Maintained: Buy
Price Target: $71
Current: $7.04
Upside: n/a
Jun 25, 2019
Maintained: Buy
Price Target: $36 → $25
Current: $1.71
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $102.21
Upside: n/a
Nov 5, 2018
Maintained: Buy
Price Target: $35
Current: $0.62
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $437.22
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $52.46
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $220.93
Current: $7.45
Upside: n/a
Jun 24, 2015
Maintained: Buy
Price Target: $160
Current: $295.63
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $16.68
Upside: n/a